Clinical Trials Logo

Clinical Trial Summary

Study MO42623 is a Phase IV, multicenter, open-label, three cohort study designed to evaluate the impact of emicizumab prophylaxis on overall health, physical activity, and joint outcomes in participants aged ≥13 and <70 years with severe hemophilia A without factor VIII (FVIII) inhibitors or moderate hemophilia A without FVIII inhibitors who are receiving FVIII prophylaxis and who will start emicizumab treatment as part of this study.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05181618
Study type Interventional
Source Hoffmann-La Roche
Contact Reference Study ID Number: MO42623
Phone 888-662-6728 (U.S. Only)
Email [email protected]
Status Not yet recruiting
Phase Phase 4
Start date January 31, 2022
Completion date October 17, 2026

See also
  Status Clinical Trial Phase
Withdrawn NCT01051544 - Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive N/A
Completed NCT02172950 - An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A Phase 3
Completed NCT01051076 - Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced) N/A
Completed NCT03376516 - Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A Phase 3
Completed NCT01181128 - Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A Phase 3
Completed NCT02083965 - Pharmacokinetics of rFVIIIFc at Two Vial Strengths Phase 1
Completed NCT01085344 - Canadian Hemophilia Prophylaxis Study Phase 4
Recruiting NCT04864743 - A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection Phase 1
Completed NCT01341912 - Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs) Phase 3
Completed NCT01125813 - Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A Phase 3
Active, not recruiting NCT04046848 - Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A Phase 1/Phase 2
Terminated NCT01405742 - Hemophilia Adult Prophylaxis Study Phase 3
Active, not recruiting NCT00323856 - Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A Phase 4
Not yet recruiting NCT05127681 - Bone Microarchitecture in Men With Hemophilia N/A
Recruiting NCT04431726 - A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors Phase 3
Completed NCT01712438 - Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients Phase 3
Completed NCT02954575 - Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A Phase 3
Completed NCT01027377 - Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A Phase 1
Withdrawn NCT02196207 - Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform Phase 3
Completed NCT02502149 - Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale Phase 3